T.H.A.C (The Healthy Aging Company) a biopharmaceutical Company which develops a new class of drugs for the early treatment of type 2 diabetes mellitus (T2DM), announces the acquisition of an international patent submitted by INSERM, Hospitals of Paris, INRA, and University of Paris.
This patent protects the drug candidate of THAC and its use for the protection of oxygen sensitive bacteria, for example in the gut microbiota. The Company reserves the right to submit a divisionary application in the coming months.
“Our drug candidate, by acting directly on the human microbiota and by tackling insulin resistance as the root cause of T2DM, has a real potential to modify the progression of the disease and to change the game for patient’s management” according to Professor Christian Bréchot, co-founder and chairman of the board of the Company.
“This acquisition is essential for the growth of the Company. It allows to reinforce our robust patent portfolio as well as to develop a competitive oral formulation for our product. With this patent, we accelerate our development, and we strengthen our competitive position on the market. The axis of the microbiota and T2DM is highly promising to finally stop and cure the disease” outlines Lyse Santoro, chief executive officer of the Company.
The « First in Class » drug candidate developed by the Company, incorporates the active ingredient ALF-5755. This is a recombinant protein derived from a human antimicrobial protein which contributes to the innate enteric immune system and drives the balance between pathogens and commensal bacterial in the microbiota while preserving the integrity of the intestinal wall. This direct action on the microbiota composition strengthens the unique and innovative mode of action of ALF-5755 to fight the insulin resistance which is responsible for a high glycemia in T2DM patients.
The dysbiosis, disequilibrium of the gut flora in humans, is characterized by complex changes in the microbiota and its various micro-organisms. Robust experimental data demonstrate that a gut dysbiosis is associated to the pathogenesis of many human diseases including intestinal and metabolic diseases such as obesity and type 2 diabetes. Indeed Dysbiosis acts alters gut wall integrity and lead to the production of metabolites which affect the sensibilization to insulin.
Type 2 diabetes Mellitus is the first worldwide non-infectious pandemics and represents a huge medical and economic burden with strong consequences on patients, professionals, healthcare organizations as well as states. The T2DM pandemics also contributes to an increased morbidity in the context of infectious diseases, such as Covid19. Despite the recent progress made for the T2DM patient management, the Worldwide Healthcare Organization alerts on a real unmet medical need and claims for the necessity to develop new drugs able to modify or even stop the progression of the disease by fighting insulin resistance, the root cause of the disease. Thanks to the unique and innovative mode of action of the active substance ALF-5755, the drug candidates of THAC tackles insulin resistance with a real potential of disease modifier while securing a long-term safety profile and preventing side effects and complications. The aim is to stem the worldwide pandemics, to improve the patient’s quality of life, to decrease pre-mortality and healthcare associated costs.
